Description: Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co.'s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer medication, vitamins, food preservative, flavoring agent, and sweetening material. Co. is also engaged in the manufacture and sale of pharmaceutical production system and machines.
Home Page: www.eisai.co.jp
4-6-10, Koishikawa
Tokyo,
112-8088
Japan
Phone:
81 3 3817 3700
Officers
| Name | Title |
|---|---|
| Mr. Haruo Naito | CEO, Representative Corp. Officer & Director |
| Mr. Gary Hendler | Sr. VP & Pres of EMEA Region |
| Dr. Lynn D. Kramer FAAN, M.D. | VP & Chief Clinical Officer - Alzheimer's Disease and Brain Health |
| Ms. Yanhui Feng | Sr. VP |
| Dr. Nadeem Sarwar Ph.D. | Pres |
| Mr. Tatsuyuki Yasuno | Sr. VP, CFO & Chief IR Officer |
| Mr. Kenta Takahashi | Exec. VP, Gen. Counsel & Intellectual Property Internal Audit |
| Mr. Yosuke Akita | VP, Chief Compliance Officer & Chief Information Security Officer |
| Ms. Sayoko Sasaki | VP of Corp. Communications & ESG |
| Mr. Teruyuki Masaka | VP & Chief HR Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 42.3729 |
|---|---|
| Trailing PE: | 77.0941 |
| Price-to-Book MRQ: | 3.3325 |
| Price-to-Sales TTM: | 0.0266 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 11092 |